Loading
Accustem Sciences Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CERRONE GABRIELE M, was filed 16 Jun 2025.
Insider Decl.
17
Thresholds
n/a
Buy Volume
€215,542
17 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGabriele M. Cerrone10 buys
Since the insiders bought
- -77.3%Entry US$1.02 · Close at T+365 US$0.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.15
Analyst consensus
Income statement
EBITDA-US$1.8M
Net income-US$1.8M0.0% margin
Valuation
Beta1.89
Balance sheet & cash
Market capUS$2.4M
Total debtUS$22.5k
Free Cash Flow-US$850.4k
Profitability & ownership
ROA-64.2%
% insiders50.9%
% institutions0.0%
Last declaration on 16 June 2025
Declarations17 total
400 shares@ US$1.100.2% of flowCommon StockSEC:0001641172-25-015197:1
Canonical exit: 11 Sept 2025 (T+90)
2,000 shares@ US$1.000.9% of flowCommon StockSEC:0001641172-25-015197:0
Canonical exit: 11 Sept 2025 (T+90)
8,991 shares@ US$0.833.0% of flowCommon StockSEC:0001641172-25-015003:1
Canonical exit: 10 Sept 2025 (T+90)
28,205 shares@ US$0.394.8% of flowCommon StockSEC:0001641172-25-015003:0
Canonical exit: 9 Sept 2025 (T+90)
3,000 shares@ US$0.670.9% of flowCommon StockSEC:0001641172-25-003618:1
Canonical exit: 8 Jul 2025 (T+90)
35,000 shares@ US$0.66510.6% of flowCommon StockSEC:0001641172-25-003618:0
Canonical exit: 7 Jul 2025 (T+90)
100,000 shares@ US$0.44720.5% of flowCommon StockSEC:0001641172-25-003222:0
Canonical exit: 16 Jun 2025 (T+90)
17,802 shares@ US$0.6095.0% of flowCommon StockSEC:0001641172-25-003222:1
Canonical exit: 6 Jul 2025 (T+90)
35,000 shares@ US$0.6510.4% of flowCommon StockSEC:0001641172-25-003222:2
Canonical exit: 6 Jul 2025 (T+90)
100,000 shares@ US$0.38118.4% of flowCommon StockSEC:0001493152-25-000211:0
Canonical exit: 31 Mar 2025 (T+90)
5,000 shares@ US$1.403.3% of flowCommon StockSEC:0001493152-23-000064:0
Canonical exit: 30 Mar 2023 (T+90)
3,729 shares@ US$1.422.5% of flowCommon StockSEC:0001493152-22-034396:0
Canonical exit: 2 Mar 2023 (T+90)
24,500 shares@ US$1.0512.4% of flowCommon StockSEC:0001493152-22-033239:0
Canonical exit: 16 Feb 2023 (T+90)
10,000 shares@ US$0.793.9% of flowCommon StockSEC:0001493152-22-020942:0
Canonical exit: 30 Oct 2022 (T+90)
20,000 shares@ US$0.504.7% of flowCommon StockSEC:0001493152-22-016256:0
Canonical exit: 6 Sept 2022 (T+90)
5,266 shares@ US$1.493.4% of flowCommon StockSEC:0001493152-22-011318:1
Canonical exit: 25 Jul 2022 (T+90)
4,181 shares@ US$1.352.6% of flowCommon StockSEC:0001493152-22-011318:0
Canonical exit: 24 Jul 2022 (T+90)
17 of 17 declarations
About Accustem Sciences Inc.
Accustem Sciences Inc. has a single filer: Gabriele M. Cerrone, a director, who signs all 17 filings in the record, every one a purchase. Published between April 27, 2022 and June 16, 2025, they total EUR 215,542, with a median of EUR 7,699. No sale, grant or option exercise is filed.
The three largest purchases are EUR 40,937 on March 18, 2025, EUR 36,613 on December 31, 2024 and EUR 24,827 on November 18, 2022. The calendar is uneven: 6 filings in 2022, one in 2023, none in 2024 and 10 in 2025. This US health care company, listed on Nasdaq, is valued at USD 2.4 million, and its sole insider holds 50.9% of it.
Read moreShow less
Thirteen of these purchases have a 90-day return on file, with a median of 44.1% and 54% positive; these are past results on record, not a forecast. Nothing new was published over the past twelve months.
